Massive study probes cancer link in common diabetes drug
NCT ID NCT02695121
First seen Apr 19, 2026 · Last updated May 24, 2026 · Updated 5 times
Summary
This large study looked at over 2 million people with type 2 diabetes to see if those taking dapagliflozin had a different risk of breast or bladder cancer compared to those on other diabetes medications. Researchers tracked cancer cases for up to 12 years. The goal was to understand safety, not to treat or prevent cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Research Site
Wilmington, Delaware, United States
-
Research Site
Washington D.C., District of Columbia, United States
-
Research Site
Utrecht, Netherlands
-
Research Site
London, United Kingdom
Conditions
Explore the condition pages connected to this study.